AbCellera Biologics Inc. (ABCL)

Balance-sheet liquidity is strong (current ratio ~12.8; about $540M cash/marketable securities per the latest 10-Q) and there is no going‑concern warning. However, the company remains loss-making with negative free cash flow, and valuation is high relative to current revenue (EV/Sales ~48x) with negative DCF outputs. Overall: well-funded, but fundamentals are still dominated by pipeline execution risk.

Post-catalyst digestion with no forward driver: the Aug 10 ABCL635 Phase 2 data pop and the Aug 13 $200M raise sit ~5 weeks behind, the sentiment delta has cooled determinately from +0.50 to +0.03, and the only actionable catalyst is a rumored options-flow signal — an Absent setup. Red-Flag Screen clean, no caps applied.

Trend frame is fully bullish: price 11.67 sits above SMA20 (11.46), SMA50 (8.89), SMA200 (5.40), EMA9 (11.29), EMA21 (10.91) and daily VWAP (11.505), with the moving averages in ascending order. Momentum is positive but decelerating: RSI14 60.88, Williams %R -40.27, MACD line +0.59 above zero but below its signal (+0.78), histogram -0.19 narrowing from -0.29 over the past week. ADX14 28.91 confirms a strong trend, and with price above every key average that trend is up. ATR14 0.70 (6.0% of price) gives a tradable range. Liquidity is ample: 20-day average dollar volume $57.3M vs the $5M floor. No earnings, dividend or split events land inside the holding window (confirmed Q3 earnings 2026-11-05 is outside). The chart reads as a 4 — a strong uptrend pressing the August highs with one weak signal (negative MACD histogram, price extended ~31% above the SMA50). However, qualitativeScore of 2 fails the required floor of 3, which is a hard block: the trade plan is not built and the action is Do Nothing regardless of chart quality.